In vitro inhibitory effects of Friedelin on human liver cytochrome P450 enzymes

Context: Friedelin is a triterpenoid with several biological activities. However, the affects of Friedelin on the activity of human liver cytochrome P450 (CYP) enzymes remains unclear. Objective: This study investigates the inhibitory effects of Friedelin on the major human liver CYP isoforms (CYP3A...

Full description

Bibliographic Details
Main Authors: Jinlan Wei, Hongying Zhang, Qingling Zhao
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:Pharmaceutical Biology
Subjects:
Online Access:http://dx.doi.org/10.1080/13880209.2018.1491999
_version_ 1818683376246194176
author Jinlan Wei
Hongying Zhang
Qingling Zhao
author_facet Jinlan Wei
Hongying Zhang
Qingling Zhao
author_sort Jinlan Wei
collection DOAJ
description Context: Friedelin is a triterpenoid with several biological activities. However, the affects of Friedelin on the activity of human liver cytochrome P450 (CYP) enzymes remains unclear. Objective: This study investigates the inhibitory effects of Friedelin on the major human liver CYP isoforms (CYP3A4, 1A2, 2A6, 2E1, 2D6, 2C9, 2C19 and 2C8). Materials and methods: First, the inhibitory effects of Friedelin (100 μM) on the eight human liver CYP isoforms were investigated in vitro using human liver microsomes (HLMs), and then enzyme inhibition, kinetic studies, and time-dependent inhibition studies were conducted to investigate the IC50, Ki and Kinact/KI values of Friedelin. Results: The results indicate that Friedelin inhibited the activity of CYP3A4 and 2E1, with the IC50 values of 10.79 and 22.54 μM, respectively, but other CYP isoforms were not affected. Enzyme kinetic studies showed that Friedelin is not only a noncompetitive inhibitor of CYP3A4, but also a competitive inhibitor of CYP2E1, with Ki values of 6.16 and 18.02 μM, respectively. In addition, Friedelin is a time-dependent inhibitor of CYP3A4 with Kinact/Ki value of 4.84 nM/min. Discussion and conclusion: The in vitro studies of Friedelin with CYP isoforms suggested that Friedelin has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP3A4 and 2E1. Further clinical studies are needed to evaluate the significance of this interaction.
first_indexed 2024-12-17T10:33:45Z
format Article
id doaj.art-7c57a3f19d7743589ef40506ef1a1126
institution Directory Open Access Journal
issn 1388-0209
1744-5116
language English
last_indexed 2024-12-17T10:33:45Z
publishDate 2018-01-01
publisher Taylor & Francis Group
record_format Article
series Pharmaceutical Biology
spelling doaj.art-7c57a3f19d7743589ef40506ef1a11262022-12-21T21:52:28ZengTaylor & Francis GroupPharmaceutical Biology1388-02091744-51162018-01-0156136336710.1080/13880209.2018.14919991491999In vitro inhibitory effects of Friedelin on human liver cytochrome P450 enzymesJinlan Wei0Hongying Zhang1Qingling Zhao2Yidu Central Hospital of WeifangYidu Central Hospital of WeifangYidu Central Hospital of WeifangContext: Friedelin is a triterpenoid with several biological activities. However, the affects of Friedelin on the activity of human liver cytochrome P450 (CYP) enzymes remains unclear. Objective: This study investigates the inhibitory effects of Friedelin on the major human liver CYP isoforms (CYP3A4, 1A2, 2A6, 2E1, 2D6, 2C9, 2C19 and 2C8). Materials and methods: First, the inhibitory effects of Friedelin (100 μM) on the eight human liver CYP isoforms were investigated in vitro using human liver microsomes (HLMs), and then enzyme inhibition, kinetic studies, and time-dependent inhibition studies were conducted to investigate the IC50, Ki and Kinact/KI values of Friedelin. Results: The results indicate that Friedelin inhibited the activity of CYP3A4 and 2E1, with the IC50 values of 10.79 and 22.54 μM, respectively, but other CYP isoforms were not affected. Enzyme kinetic studies showed that Friedelin is not only a noncompetitive inhibitor of CYP3A4, but also a competitive inhibitor of CYP2E1, with Ki values of 6.16 and 18.02 μM, respectively. In addition, Friedelin is a time-dependent inhibitor of CYP3A4 with Kinact/Ki value of 4.84 nM/min. Discussion and conclusion: The in vitro studies of Friedelin with CYP isoforms suggested that Friedelin has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP3A4 and 2E1. Further clinical studies are needed to evaluate the significance of this interaction.http://dx.doi.org/10.1080/13880209.2018.1491999cyp3a4cyp2e1drug–drug interactions
spellingShingle Jinlan Wei
Hongying Zhang
Qingling Zhao
In vitro inhibitory effects of Friedelin on human liver cytochrome P450 enzymes
Pharmaceutical Biology
cyp3a4
cyp2e1
drug–drug interactions
title In vitro inhibitory effects of Friedelin on human liver cytochrome P450 enzymes
title_full In vitro inhibitory effects of Friedelin on human liver cytochrome P450 enzymes
title_fullStr In vitro inhibitory effects of Friedelin on human liver cytochrome P450 enzymes
title_full_unstemmed In vitro inhibitory effects of Friedelin on human liver cytochrome P450 enzymes
title_short In vitro inhibitory effects of Friedelin on human liver cytochrome P450 enzymes
title_sort in vitro inhibitory effects of friedelin on human liver cytochrome p450 enzymes
topic cyp3a4
cyp2e1
drug–drug interactions
url http://dx.doi.org/10.1080/13880209.2018.1491999
work_keys_str_mv AT jinlanwei invitroinhibitoryeffectsoffriedelinonhumanlivercytochromep450enzymes
AT hongyingzhang invitroinhibitoryeffectsoffriedelinonhumanlivercytochromep450enzymes
AT qinglingzhao invitroinhibitoryeffectsoffriedelinonhumanlivercytochromep450enzymes